Preparing chemotherapy for cancer patients at Canadian hospitals is potentially prone to errors, say researchers who embedded themselves in the system to see what improvements could be made.

Since a cancer patient in Edmonton died in 2006 after an infusion pump was wrongly programmed to deliver a strong dose of fluorouracil over four hours instead of four days as intended, oncologists, pharmacists, nurses and researchers have been searching for ways to prevent a similar occurrence.

Now Rachel White, a human factors specialist at Toronto's University Health Network, and her team have adapted an approach that anthropologists use to learn about native cultures.

Their aim is to explore how common the sources of error are in hospitals and to find safer options by giving health-care workers on the frontlines an authoritative voice.

"We don't want people to be afraid," White reassured patients Tuesday in an interview with CBC News, noting the health care field is full of well trained professionals helping people.

"The power of taking the human factors approach is that we have a special lens to look at the world with, and that lens allows us to see problems before they happen."

Safety-critical industries like aviation and nuclear plants apply engineering design principles and the research methods of psychology to prevent human errors. White would like to see them applied more in Canadian hospitals.

Writing in the Journal of Oncology Pharmacy Practice, White's team concluded that widespread changes in Canadian oncology pharmacies are necessary.

For the exploratory study, White and co-author Andrea Cassano-Piche embedded themselves at six cancer treatment centres of various sizes across the country for one week each in 2008 and 2009. They observed and interviewed medical oncologists, oncology pharmacists, pharmacy technicians, oncology nurses and administrative clerks as they did their work.

The potential errors they identified wouldn't normally be picked up, so the frequency is unknown, but the impacts are potentially catastrophic.

The solutions, which are already being adopted, include:

- Working with just one chemotherapy preparation at a time in the hospital pharmacy's safety cabinet to prevent mixing errors.

- Keeping the correct label and its bag paired at all times instead of piling orders separately like a short-order cook's.

- Having a second person check that the volume and concentration of chemotherapy is correct when drugs aren't available in a ready-to-use liquid form.

White praised co-author Dr. Tony Fields, head of Edmonton's Cross Cancer Institute, for his courage in admitting the error and working with colleagues across the country to identify the issues and introduce the changes.

A broader 2011 report by the same team reported more than 230 adverse events involving chemotherapy in Canada, though some may have been duplicates.

Since then, hospital staff members have received more training on operating the pumps and clearer, pre-printed order forms are now used.

A 2004 study estimated that preventable medical errors in hospital contribute to between 9,000 and 24,000 deaths in Canada a year. Other safety measures have been introduced since then, such as surgical checklists.

Also on HuffPost:

Loading Slideshow...
  • 1. Deadly Form Of Breast Cancer Decoded

    Triple negative breast cancer is a difficult form of cancer to treat, but for the first time ever, an international team of scientists have decoded its genetic makeup. Knowing more about these genes could change the way the disease is diagnosed and change treatments for the next generation, creating more personalized care.

  • 2. New Ways To Treat Malignant Childhood Brain Cancer

    Dr. Michael Taylor, based in Toronto, was part of the international MAGIC (Medulloblastoma Advanced Genomics International Consortium) team of experts that identified abnormalities that lead to the development of the malignant brain tumour medulloblastama. This discovery has identified more effective treatments and may spare children the side effects of unnecessary radiation.

  • 3. Improving Survival For Patients With Rare Form Of Pancreatic Cancer

    Though there are typically poor survival rates for those living with pancreatic cancer, new findings may improve these rates of survival. An NCIC Clinical Trials Group study found that patients with a rare form of pancreatic cancer – <a href="http://en.wikipedia.org/wiki/Periampullary_cancer">periampullary adenocarcinoma</a> – live longer if they are treated with surgery as well as chemotherapy.

  • 4. Hodgkin Lymphoma Patients Live Longer With Chemotherapy Alone

    A trial led by the NCIC Clinical Trials Group found that patients with limited-stage Hodgkin lymphoma live longer when treated with standard chemotherapy, compared with those who are also receiving radiation. This will allow patients to avoid long-term side effects of radiation.

  • 5. Key Barriers To Palliative Care Identified

    A study led by Dr. Camilla Zimmermann in Toronto found that Canadian oncologists refer terminally ill cancer patients to palliative care too late — sometimes not until the final few days. The availability and comprehensiveness of palliative care services were identified as key barriers. It was found that referring patients earlier allows care teams to relieve symptoms and distress, provide appropriate social services, and give advanced care advice to improve the quality of life for cancer patients.

  • 6. Natural Sea Sponge Can Prevent Muscle Wasting

    Muscle wasting, also referred to as <a href="http://en.wikipedia.org/wiki/Cachexia">Cachexia</a>, is the loss of weight or muscle often induced by cancer. Approximately 30 per cent of people with cancer die due to muscle wasting. Dr. Imed Gallouzi and his research team in Montreal found that a natural product from sea sponges prevents muscle wasting in mice. This study is the first to show a potential treatment option for those affected by muscle wasting.

  • 7. Drug Destroys Human Cancer Stem Cells But Spares Healthy Ones

    Dr. Mick Bhatia, an international leader in cancer stem cell research, discovered that the drug <a href="http://en.wikipedia.org/wiki/Thioridazine">thioridazine</a> can successfully kill cancer stem cells responsible for initiating leukemias without causing any harm to normal stem cells. This is an important discovery, as cancer stem cells can sustain the growth of cancer and are also a common factor in cancer recurrence.

  • 8. Smarter Treatments Developed For Rare Young Adult Cancer

    Dr.Torsten Nielsen and his Vancouver-based research team have unravelled how the genetic mutation which leads to the growth of a rare and often fatal form of cancer (<a href="http://en.wikipedia.org/wiki/Synovial_sarcoma">synovial sarcoma</a>) interacts with proteins to cause cancer. The researchers found that there are certain drugs used to suppress these proteins that can kill tumour cells.

  • 9. Vitamin D Controls Proteins To Stop The Growth Of Cancer

    Dr. John White and his research group in Montreal studied a protein called the <a href="http://en.wikipedia.org/wiki/Myc">cMYC protein</a>, which is elevated in at least 50 per cent of cancers. Researchers found that vitamin D can block cMYC. This evidence will spark future studies to understand the role Vitamin D plays in stopping cancer development and growth.

  • 10. Mefloquine Drug Shows Promise In Fighting Cancer

    <a href="http://en.wikipedia.org/wiki/Acute_myeloid_leukemia">Acute myeloid leukemia</a> (AML) is a cancer of the blood and bone marrow that can become severe if not treated quickly. Dr. Aaron Schimmer and colleagues in Toronto tested several drugs to determine whether any of them could target AML cells. The researchers found that <a href="http://en.wikipedia.org/wiki/Mefloquine">mefloquine</a>, a medication generally used to treat malaria, specifically causes AML cancer cells to burst.